Physician profile
Wanda V Harrison
NPI 1124165972
$5,343.00
in general payments reported to CMS, 2019-2025
37 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $545 · 2021: $672 · 2022: $889 · 2023: $940 · 2024: $745 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.89 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.18 | 2019-2025 | |
| Lilly USA, LLC | $579.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $525.38 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $499.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $271.56 | 2019-2023 | |
| Abbott Laboratories | $254.74 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $247.26 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $216.43 | 2020-2025 | |
| Novo Nordisk INC | $200.01 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Gilead Sciences, INC. | $160.62 | 2019-2025 | |
| Amgen INC. | $141.44 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.51 | 2019-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $132.35 | 2022 | |
| Merck Sharp & Dohme LLC | $132.22 | 2020-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $81.19 | 2021-2024 | Trintellix |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.